Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Accumulated Depreciation & Amortization (2019 - 2024)

Summit Therapeutics' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $1.1 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 7.29% year-over-year to $1.1 million; the TTM value through Dec 2024 reached $1.1 million, up 7.29%, while the annual FY2024 figure was $1.1 million, 7.29% up from the prior year.
  • Accumulated Depreciation & Amortization reached $1.1 million in Q4 2024 per SMMT's latest filing, up from $1.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.3 million in Q4 2022 to a low of $1.0 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 2616.62% in 2020, then decreased 19.66% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.1 million in 2020, then fell by 8.24% to $1.0 million in 2021, then increased by 25.19% to $1.3 million in 2022, then fell by 19.66% to $1.0 million in 2023, then rose by 7.29% to $1.1 million in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Accumulated Depreciation & Amortization are $1.1 million (Q4 2024), $1.0 million (Q4 2023), and $1.3 million (Q4 2022).